Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer

Journal of the National Cancer Institute

Volumn 107, Issue 8, 2015, Pages

  Carvajal Hausdorf, Daniel E ^a   Schalper, Kurt A ^a   Pusztai, Lajos ^a   Psyrri, Amanda ^b   Kalogeras, Konstantine T ^c,d   Kotoula, Vasiliki ^e   Fountzilas, George ^d,e   Rimm, David L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^c Hellenic Cooperative Oncology Group   (Greece)

^d PAPAGEORGIOU GENERAL HOSPITAL   (Greece)

^e ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TUMOR MARKER;

ANTIBODY TITER; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; COHORT ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; FLUORESCENCE; GENE AMPLIFICATION; HUMAN; IMMUNOFLUORESCENCE; IN SITU HYBRIDIZATION; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POPULATION DISTRIBUTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; STANDARDIZATION; TISSUE MICROARRAY; ADJUVANT CHEMOTHERAPY; ADULT; AGED; BREAST NEOPLASMS; CHEMISTRY; CLINICAL TRIAL (TOPIC); EXTRACELLULAR SPACE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; INTRACELLULAR SPACE; MIDDLE AGED; MORTALITY; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; EXTRACELLULAR SPACE; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SPACE; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, ERBB-2; SENSITIVITY AND SPECIFICITY; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84939456648     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv136     Document Type: Article

References (21)

1. Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997-4013.
2. College of American Pathologists. Participant Summary. HER2-A immunohistochemistry Tissues microarray. Surveys 2013 and Anatomic Pathology Education Programs.
3. Rhodes A, Sarson J, Assam EE, Dean SJ, Cribb EC, Parker A. The reliability of rabbit monoclonal antibodies in the immunohistochemical assessment of estrogen receptors, progesterone receptors, and HER2 in human breast carcinomas. Am J Clin Pathol. 2010;134(4):621-632.
4. Nunes CB, Rocha RM, Buzelin MA, et al. False positivity in HER2 testing of breast cancer: novel paths for approaching an old dilemma. J Clin Pathol. 2013;66(11):946-950.
5. Dekker TJ, Borg ST, Hooijer GK, et al. Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach. Breast Cancer Res. 2012;14(3):R93.
6. Ricardo SA, Milanezi F, Carvalho ST, Leitão DR, Schmitt FC. HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas. J Clin Pathol. 2007;60(9):1001-1005.
7. Nunes CB, Rocha RM, Reis-Filho JS, et al. Comparative analysis of six different antibodies against Her2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridisation in breast carcinomas. J Clin Pathol. 2008;61(8):934-938.
8. Arribas J, Baselga J, Pedersen K, Parra-Palau JL. p95HER2 and breast cancer. Cancer Res. 2011;71(5):1515-1519.
9. Eroglu Z, Tagawa T, Somlo G. Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer. Oncologist. 2014;19(2):135-150.
10. Giltnane JM, Rimm DL. Technology insight: Identification of biomarkers with tissue microarray technology. Nat Clin Pract Oncol. 2004;1(2):104-111.
11. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med. 2002;8(11):1323-1327.
12. Neumeister VM, Anagnostou V, Siddiqui S, et al. Quantitative assessment of effect of preanalytic cold ischemic time on protein expression in breast cancer tissues. J Natl Cancer Inst. 2012;104(23):1815-1824.
13. Velcheti V, Schalper KA, Carvajal DE, et al. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest. 2014;94(1):107-116.
14. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19:335-351, correction: 2001; 20:655.
15. Fountzilas G, Dafni U, Papadimitriou C, et al. Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial. BMC Cancer. 2014;14(1):515.
16. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25(1):118-145.
17. Cantaloni C, Tonini RE, Eccher C, et al. Diagnostic value of automated Her2 evaluation in breast cancer: a study on 272 equivocal (score 2+) Her2 immunoreactive cases using an FDA approved system. Appl Immunohistochem Mol Morphol. 2011;19(4):306-312.
18. Zabaglo L, Stoss O, Rüschoff J, Zielinski D, Salter J, Arfi M. HER2 staining intensity in HER2-positive disease: relationship with FISH amplification and clinical outcome in the HERA trial of adjuvant trastuzumab. Ann Oncol. 2013;24(11):2761-2766.
19. McCabe A, Dolled-Filhart M, Camp RL, Rimm DL. Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst. 2005;97(24):1808-1815.
20. Rimm DL. What brown cannot do for you. Nat Biotechnol. 2006;24(8):914-916.
21. Perez EA, Press MF, Dueck AC. Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005). Breast Cancer Res Treat. 2013;138(1):99-108.